FBRX - CIK 0001419041
The table below shows Forte Biosciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $58.22M | $93.41M | $106.14M | $45.86M | $16.36M | $24.50M |
| Short-term investments | - | $36.12M | $36.12M | $36.12M | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $65.11M |
| $95.41M |
| $107.62M |
| $47.16M |
| $17.67M |
| $25.71M |
| Property, plant & equipment | $110.00K | $148.00K | $110.00K | $125.00K | $86.00K | $96.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $67.22M | $97.09M | $107.78M | $47.46M | $17.95M | $26.08M |
| Accounts payable | $13.08M | $5.49M | $5.30M | $5.02M | $5.16M | $5.28M |
| Total current liabilities | $23.65M | $12.99M | $9.17M | $9.03M | $8.58M | $9.12M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $25.12M | - | - | - | - | - |
| Retained earnings | -$245.51M | -$198.59M | -$180.90M | -$169.65M | -$146.84M | -$138.45M |
| Total equity | $42.10M | $84.10M | $98.61M | $38.43M | $9.37M | $16.96M |